Pazopanib
| Name | Pazopanib |
|---|---|
| Supplier | Cell Signaling Technology |
| Catalog | 12466 |
| Prices | $126.00 |
| Sizes | 10 mg |
| Formula | C21H23N7O2S |
| Molecular Weight | 437.52 g/mol |
| Purity | >99% |
| Description | Pazopanib is a multikinase inhibitor that potently targets VEGFR1 (IC 50 = 10 nM), VEGFR2 (IC 50 = 30 nM), VEGFR3 (IC 50 = 47 nM), PDGFRα (IC 50 = 71 nM), PDGFRβ (IC 50 = 84 nM), and c-Kit (IC 50 = 74 nM) tyrosine kinases involved in tumor progression and angiogenesis, and can also inhibit many other tyrosine kinases at nanomolar concentrations (1). Research studies have demonstrated that pazopanib effectively blocks ligand-induced autophosphorylation of VEGFR2, PDGFRβ, and c-Kit in vitro (1,2), and selectively inhibits VEGF-induced HUVE cell proliferation over FGF (IC 50 = ~21 nM vs ~720 nM). Investigators have demonstrated that pazopanib inhibits the growth, survival, and migration of multiple myeloma (MM) cell types (3). |
| Supplier Page | Shop |
Product images
Western blot analysis of extracts from NCI-H526 cells, serum-starved overnight and untreated (-) or treated with Human Stem Cell Factor (hSCF) #8925 (100 ng/ml, 5 min; +) either with our without pazopanib pre-treatment (1 µM, 2 hr; +), using Phospho-c-Kit (Tyr703) (D12E12) Rabbit mAb #3073 (upper) or c-Kit (D13A2) XP ® Rabbit mAb #3074 (lower).
Western blot analysis of extracts from HUVE cells, serum-starved overnight and untreated (-) or treated with Human Vascular Endothelial Growth Factor (hVEGF 165 ) #8065 (50 ng/ml, 5 min; +) either with our without pazopanib pre-treatment (1 µM, 2 hr; +), using Phospho-VEGF Receptor 2 (Tyr1175) (19A10) Rabbit mAb #2478 (upper) or VEGF Receptor 2 (55B11) Rabbit mAb #2479 (lower).
Chemical structure of pazopanib.